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Background: Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) provide useful prognostic 
predictors in patients after cardiac surgery. However, predictive accuracy of NT-proBNP levels has varied significantly 
according to renal dysfunction. The purpose of this study was to assess whether preoperative NT-proBNP levels could 
be used as predictors of early postoperative outcomes on the basis of renal function in patients undergoing off-pump 
coronary artery bypass surgery (OPCAB). 
Methods: In 219 patients undergoing elective OPCAB, NT-proBNP and an estimated glomerular filtration rate (eGFR) 
were assessed preoperatively. All patients were divided into 3 groups according to tertiles of eGFR: the first (eGFR ≥ 
90 ml/min/1.73 m2), the second (90 ml/min/1.73 m2 > eGFR ≥ 72 ml/min/1.73 m2) and the third tertile group (eGFR 
< 72 ml/min/1.73 m2). End point was the composite of early postoperative complications defined as myocardial 
infarction, new onset atrial fibrillation, ventricular dysfunction, prolonged mechanical ventilator care (> 48 hr), 
prolonged ICU stay (≥ 3 days), and in hospital mortality. 
Results: There was no difference in early postoperative complications among groups. A preoperative NT-proBNP 
level of 228 pg/ml and 302 pg/ml (sensitivity 70%, specificity 67%, P < 0.001 and sensitivity 73%, specificity 63%, P 
= 0.001, respectively) were optimal cut-off values predicting complicated early postoperative course in second and 
third tertile group, respectively.
Conclusions: Preoperative NT-proBNP levels seem to be predictive of early postoperative complications in patients 
with eGFR < 90 ml/min/1.73 m2 undergoing OPCAB. (Korean J Anesthesiol 2011; 61: 35-41)
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Introduction 
    Off-pump coronary artery bypass surgery (OPCAB) has been 
widely used even in high-risk patients. However, displacement 
of the heart and occlusion of native coronary arteries may lead 
to ischemia and hemodynamic instability, resulting in potential 
postoperative complications despite the reported benefits of 
OPCAB without cardiopulmonary bypass [1-3]. Biomarkers that 
could predict patients at high risk of early postoperative course, 
either alone or in combination with existing clinical scoring 
systems, would be of considerable value to anesthesiologists. 
    Plasma levels of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) provide useful prognostic predictors not only 
in patients with congestive heart failure or acute coronary 
syndrome, but also in patients who underwent cardiac surgery 
[4-6]. In addition, preoperative plasma levels of NT-proBNP 
have been reported to be predictive for early postoperative 
cardiovascular complications in patients following OPCAB 
[5]. However, predictive accuracies of NT-proBNP levels have 
varied significantly according to multiple clinical factors 
including cardiac systolic and diastolic dysfunction, age, and 
renal dysfunction [7-11]. Subclassification on the basis of these 
factors, especially renal function, which has been shown to be a 
major determinant of plasma NT-proBNP levels, might improve 
predictive accuracies of NT-proBNP based prediction of early 
postoperative complications. However, there are limited studies 
on the predictive utility of plasma NT-proBNP levels according 
to preoperative renal function for postoperative cardiovascular 
morbidity in patients after cardiac surgery [6,7]. 
    The purpose of this study was to assess whether preoperative 
NT-proBNP levels could be used as prognostic predictors for 
early postoperative outcomes on the basis of renal function in 
patients following OPCAB. 
Materials and Methods
    After obtaining Institutional Review Board approval, a total 
of 219 consecutive patients scheduled for elective OPCAB from 
January 2008 to June 2010 were enrolled in this prospective 
observational study after screening for the following exclusion 
criteria: history of myocardial infarction (MI) within 1 week, 
significant valvular heart disease, emergency operation, prior 
cardiac surgery, age < 20 years, and/or renal failure requiring 
dialysis. All patients were divided into 3 groups according to 
tertiles of preoperative estimated glomerular filtration rate 
(eGFR) using the Modification of Diet in Renal Disease equation 
[12]: the first (eGFR ≥ 90 ml/min/1.73 m2), the second (90 ml/
min/1.73 m2 > eGFR ≥ 72 ml/min/1.73 m2) and the third tertile 
group (eGFR < 72 ml/min/1.73 m2). 
    Preoperative patients’ characteristics, including age, gender, 
body mass index, New York Heart Association functional 
classification [13], recent MI, diabetes mellitus, cerebrovascular 
attack, arterial hypertension, chronic obstructive pulmonary 
disease, left ventricular ejection fraction, EuroSCORE (European 
System for Cardiac Operative Risk Evaluation) [14] and medi-
cations, were assessed.
Anesthesia and surgical technique
    All patients received 0.05 to 0.1 mg/kg of morphine intra-
muscularly as premedication 1 hour before the operation. On 
arrival in the operating room, standard monitoring, such as 
lead II and V5 of ECG, arterial blood pressure, pulse-oxymetry, 
bispectral index and cerebral oxymetry, were applied with 
a pulmonary artery catheter (Swan-Ganz CCOmbo CCO/
SvO2
TM, Edwards Lifesciences LLC, Irvine, CA, USA) inserted 
in the right internal jugular vein. Anesthesia was induced 
with intravenous midazolam (0.03-0.07 mg/kg), sufentanil 
(1.5-3.0 μg/kg) and rocuronium bromide 50 mg and then 
maintained with sevoflurane (0.4-1.5%), sufentanil (0.5-1.5 
μg/kg/min) and vecuronium (1-2 μg/kg/min). Intravascular 
volume replacement was managed with crystalloid and colloid 
solutions to maintain the pulmonary capillary wedge pressure 
(PCWP) between 8 and 14 mmHg according to baseline 
values before enucleation of the heart and before volume 
status that was evaluated by intraoperative trans-esophageal 
echocardiography. Central blood temperature measured by the 
pulmonary artery catheter was maintained at approximately 
36oC with a warm mattress, forced warm air blanket and fluid 
warmer, as necessary. During the surgical procedure, mean 
arterial pressure (MAP) was maintained above 70 mmHg either 
with a 10o to 20o Trendelenburg position and/or norepinephrine 
infusion. To expose and stabilize the target coronary vessel, 
posterior pericardial stitch, large gauze (12 × 70 cm) swabs, 
and tissue stabilizer (Octopus Tissue Stabilization SystemⓇ, 
Medtronic Inc. Minneapolis, MN, USA) were used. Allogenic-
packed red blood cells were transfused when the hematocrit 
level was < 25% throughout the study period. All patients were 
transferred to the intensive care unit (ICU) after surgery. 
Postoperative management
    All patients received standardized ICU care at the discretion 
of ICU staff (cardiothoracic surgeons and anesthetists) blinded 
to this study according to the standard ICU protocols of our 
institution. Criteria for weaning from ventilatory support 
included an appropriate sensorium, hemodynamic stability 
(cardiac index > 2.2 L/min/m2; MAP > 60 mmHg; PCWP < 
20 mmHg; and no significant arrhythmias), PaO2/FiO2 > 200, 
minimal chest tube drainage, urine output > 0.5 ml/kg/h, 
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and temperature > 35.5oC. Discharging criteria from the ICU 
were as follows: stabilized patient’s clinical status without the 
need for ICU monitoring and care (which included no further 
requirement for either inotropic or vasoactive agents), and no 
plan for further active intervention.
    End point was the composite of early postoperative compli-
cations defined as MI, new onset atrial fibrillation, ventricular 
dysfunction, prolonged mechanical ventilator care (> 48 
hr), prolonged ICU stay (≥ 3 days), and mortality during 
hospitalization. Postoperative MI was defined as an increase in 
troponin-T ≥ 0.5 ng/ml (5 times above the upper normal limit) 
and a development of new pathologic Q wave or a new left 
bundle branch block [14]. Ventricular dysfunction was defined 
as the requirement for inotropes, new intra-aortic balloon 
pump or ventricular assist device support after OPCAB. 
    NT-proBNP was analyzed from routinely assessed blood 
samples one day before surgery and on postoperative day 7. 
Preoperative NT-proBNP concentrations were measured with 
electrochemiluminescence immunoassay using the Elecsys 
analyzer (Elecsys proBNP, Roche Diagnostics GmbH, Basel, 
Switzerland) one day before surgery. Creatine kinase-CK-
MB and troponin-T were also assessed before surgery and on 
postoperative days 1 and 2. 
Statistical analysis
    Continuous variables were shown as mean ± SD, and 
categorical variables were shown as a number (%). To compare 
each group, χ2/Fisher exact tests for categorical variables 
and one-way ANOVA for continuous variables were used 
as appropriate. To evaluate the utility of NT-proBNP as a 
prognostic indicator of postoperative cardiac morbidity and 
prolonged ICU stay, receiver operating characteristic (ROC) 
curves were calculated in all patients and in each tertile group of 
patients. All analysis was performed with SPSS 17.0 (SPSS Inc., 
Chicago, IL, USA). In all tests, a P value of < 0.05 was considered 
as statistically significant.
Results
    OPCAB was performed successfully in all 219 patients. Patient 
characteristics and preoperative data according to preoperative 
renal function are shown in Table 1. There were no significant 
differences among groups, except female gender, which was 
more frequent in the first tertile group than in the other groups 
(P < 0.001). The EuroSCORE was 3.3 ± 2.0 in the first tertile 
group, 2.8 ± 2.0 in the second tertile group, and 3.2 ± 1.8 in the 
third tertile group (P = 0.23).
    There were no significant differences in cardiac morbidity 
and other postoperative outcomes among groups (Table 2). 
There was one patient classified as in-hospital mortality in the 
third tertile group. Postoperative NT-proBNP levels were 2,011 ± 
4,782 pg/ml in the first tertile group, 1,461 ± 1,367 pg/ml in the 
second tertile group, and 2,035 ± 2,373 pg/ml in the third tertile 
Table 1. Patient Characteristics 
Total
(n = 219)
1st tertile 
eGFR ≥ 90
(n = 73)
2nd tertile
90 > eGFR ≥ 72
(n = 73)
3rd tertile
eGFR < 72
(n = 73)
P value
Age (years)
Female gender
BMI (kg/m2)
NYHA III-IV
Recent MI
Diabetes mellitus
CVA
Hypertension
COPD
LVEF (%)
    < 50%
EuroSCORE
NT-proBNP at baseline(pg/ml)
Hemoglobin at baseline (mg/dl)
    Medications
    β blocker
    CCB
    ACE inhibitor
    Statin
66 ± 7
71 (32)
24.4 ± 3.0
40 (18)
28 (13)
89 (41)
13 (6)
131 (60)
20 (9)
54 ± 15
61 (28)
3.1 ± 1.9
1,102 ± 2,962
13.1 ± 1.1
138 (63)
91 (42)
64 (29)
99 (45)
65 ± 12
44 (60)
24.4 ± 2.8
11 (15)
9 (12)
26 (36)
6 (12)
39 (53)
3 (4)
59 ± 14
18 (25)
3.3 ± 2.0
1,014 ± 4,135
12.9 ± 1.1
40 (55)
26 (36)
22 (30)
37 (51)
65 ± 8
16 (22)
24.3 ± 3.3
16 (22)
11 (15)
31 (42)
3 (4)
42 (57)
7 (10)
57 ± 15
20 (27)
2.8 ± 2.0
1,061 ± 1,908
13.0 ± 1.1
48 (66)
28 (38)
18 (25)
30 (41)
68 ± 7
11 (15)
24.6 ± 3.0
13 (18)
8 (11)
32 (44)
4 (5)
50 (68)
10 (14)
55 ± 15
23 (32)
3.2 ± 1.8
1,230 ± 2,419
13.1±1.4
50 (68)
37 (51)
24 (33)
32 (44)
0.07
< 0.001
0.66
0.12
0.79
0.46
0.68
0.06
0.11
0.18
0.21
0.23
0.98
0.92
0.08
0.09
0.49
0.53
Data are expressed as mean ± SD or number of patients (%). eGFR: estimate glomerular filtration rate, BMI: body mass index, NYHA: New 
York heart association functional classification, Recent MI: myocardial infarction within 1 month, CVA: cerebrovascular attack, COPD: chronic 
obstructive pulmonary disease, LVEF: left ventricular ejection fraction, EuroSCORE: European system for cardiac operative risk evaluation, NT-
proBNP: N-terminal pro-B-type natriuretic peptide, CCB: calcium channel blocker, ACE inhibitor: angiotensin converting enzyme inhibitor. 
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group, and there was no significant difference among groups (P 
= 0.613). 
    Sensitivity and specificity for early postoperative compli-
cations were combined at different concentrations of NT-
proBNP by ROC analysis (Fig. 1). The area under curve (AUC) 
using preoperative NT-proBNP to detect early postoperative 
complications was 0.668 (P < 0.001) in all patients, 0.429 in the 
first tertile group (P = 0.321), 0.780 in the second tertile group 
(95% CI, 0.668-0.892; P < 0.001), and 0.736 in the third tertile 
group (95% CI, 0.616-0.856; P = 0.001). A preoperative NT-
proBNP value of 228 pg/ml had a sensitivity of 70%, specificity 
of 67%, and accuracy of 68% in the second tertile group, 
and 302 pg/ml had a sensitivity of 73%, specificity of 63%, 
and accuracy of 66% in the third tertile group for predicting 
early postoperative complications (Table 3). The mean NT-
proBNP levels were significantly higher in patients with early 
Table 2. Early Postoperative Complications and Length of ICU and Hospital Stay
Total
(n = 219)
1st tertile
eGFR ≥ 90
(n = 73)
2nd tertile
90 > eGFR ≥ 72
(n = 73)
3rd tertile
eGFR < 72
(n = 73)
P value
Total early postoperative complications 
    Myocardial infarction
    Atrial fibrillation
    Ventricular dysfunction
    Mechanical ventilator > 48 hr
    ICU stay ≥ 3 days
    In-hospital mortality
ICU stay (days)
Length of hospital stay (days)
106 (48)
12 (5)
18 (8)
32 (15)
5 (2)
72 (33)
1 (0)
2.5 ± 1.2
15 ± 12
33 (45)
4 (5)
5 (7)
7 (10)
0 (0)
23 (32)
0 (0)
2.4 ± 0.7
13 ± 5
32 (44)
4 (5)
4 (5)
12 (16)
2 (3)
21 (29)
0 (0)
2.5 ± 1.2
14 ± 6
41 (56)
4 (5)
9 (12)
13 (18)
3 (4)
25 (34)
1 (1)
2.7 ± 1.5
19 ± 19
0.26
1.0
0.23
0.27
0.21
0.45
0.33
0.48
0.30
Data are expressed as mean ± SD or number of patients (%). eGFR: estimated glomerular filtration rate, ICU: intensive care unit. 
Fig. 1. The receiver operating characteristic curve about early postoperative complications of NT-proBNP.
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postoperative complications in the second (P = 0.002) and third 
(P = 0.01) tertile groups (Fig. 2). 
Discussion
    This study was designed to examine the predictive value of 
plasma levels of NT-proBNP for early postoperative compli-
cations after OPCAB by subclassification according to pre-
operative renal function. We found that preoperative levels of 
NT-proBNP seemed to predict early postoperative course in 
patients with eGFR < 90 ml/min/1.73 m2 following OPCAB. 
However, plasma NT-proBNP levels were not a reliable predictor 
for early postoperative outcomes in patients with eGFR ≥ 90 ml/
min/1.73 m2; therefore, predictive tools combined with clinical 
scoring systems might be needed in this population. 
    Numerous risk indices have been developed in an attempt 
to predict postoperative morbidity and mortality in patients 
undergoing cardiac surgery. Although these indices have been 
actively studied, they have been found to have questionable 
predictive value, accuracy, and overall usability in a clinical 
setting [15-19]. The prognostic value of NT-proBNP has been 
demonstrated in patients with congestive heart failure and acute 
coronary syndrome [20]. Preoperative plasma levels of NT-
proBNP are also known to predict adverse outcomes after the 
cardiac surgery, even after OPCAB without cardiopulmonary 
bypass [6,20,21]. However, plasma levels of NT-proBNP are 
affected by multiple factors such as age, cardiac systolic and 
diastolic dysfunction, blood hemoglobin concentration, and 
renal dysfunction [7-11]. Therefore, subclassification on the 
basis of preoperative renal function might improve predictive 
accuracies of NT-proBNP for prediction of postoperative 
morbidity and mortality. There are, however, only limited 
data regarding their predictive accuracies for postoperative 
outcomes after cardiac and noncardiac vascular surgery [6,8,22]. 
    Our results demonstrated that NT-proBNP was valuable 
in predicting early postoperative complications only in 
patients with eGFR < 90 ml/min/1.73 m2 undergoing OPCAB. 
Natriuretic peptides are produced in the myocardium in 
response to myocyte stretch, mainly due to pressure or volume 
overload, and subsequently split into BNP and NT-proBNP. 
Plasma NT-proBNP, which is biologically inactive and has a 
longer half-life than that of BNP (60-120 min vs. 20 min), is 
cleared by the kidneys; thus, renal function has been shown to 
be a major determinant of plasma NT-proBNP level [7,9]. Age-
related elevation of BNP has also been reported to be partially 
due to renal functional changes [10]. In patients with chronic 
kidney disease not requiring dialysis and without cardiac 
symptoms, NT-proBNP level elevation has been reported 
to reflect underlying coronary disease and left ventricular 
hypertrophy independent of renal function [23]. In addition, 
NT-proBNP concentrations were also independently associated 
with mortality in hemodialysis patients [24]. However, in 
patients undergoing noncardiac vascular surgery regardless of 
underlying cardiac disease, the prognostic value of NT-proBNP 
Table 3. Values of NT-proBNP Receiver Operating Characteristic Curve for Early Postoperative Complications
Total
(n = 219)
1st tertile
eGFR ≥ 90
(n = 73)
2nd tertile
90 > eGFR ≥ 72
(n = 73)
3rd tertile
eGFR < 72
(n = 73)
Cut-off value (pg/ml)
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
AUC
Significance
95% CI
274
  62
  62
  62
  62
0.668
0.000
0.593-0.743
172
   51
  43
  48
  47
0.429
0.321
0.285-0.572
228
  70
  67
  68
  69
0.780
0.000
0.668-0.892
302
  73
  63
  66
  70
0.736
0.001
0.616-0.856
eGFR: estimated glomerular filtration rate, NT-proBNP: N-terminal pro brain natriuretic peptide, PPV: positive predictive value, NPV: negative 
predictive value, AUC: area under curve, 95% CI: 95% confidence interval. 
Fig. 2. Mean values of NT-proBNP in each tertile groups. abbrevia-
tion: no complication, no early postoperative complications; compli-
cation, early postoperative complication. *P < 0.05 compared with 
No complication.
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for cardiac outcomes was useful only in patients with GFR ≥ 30 
ml/min/1.73 m2, most pronounced in patients with GFR ≥ 90 
ml/min/1.73 m2, but not as useful in patients with GFR < 30 ml/
min/1.73 m2 [8]. In our study, the discriminative value of NT-
proBNP was useful in patients with eGFR < 90 ml/min/1.73 m2. 
In comparison to a previous study [8], we could not evaluate the 
influence of extremely reduced renal function on the usefulness 
of NT-proBNP as a prognostic cardiac risk marker because 
there were only 3 patients with eGFR < 30 ml/min/1.73 m2. In 
addition, underlying coronary disease and decreased cardiac 
systolic function might affect the discrepancy between previous 
studies and our results in patients with GFR ≥ 90 ml/min/1.73 
m2. The inverse relationship between NT-proBNP and eGFR 
reflect not only reduced renal function, but also the presence 
of underlying coronary disease, heart failure, or plasma volume 
overload. Therefore, the optimal cut-off values and predictive 
accuracies of NT-proBNP according to preoperative renal 
function might be different between patients with cardiac 
disease and patients without cardiac disease. 
    There are some limitations in this study. This study had 
a small number of patients; therefore, results need to be 
confirmed in a larger sample population. Further study is also 
needed to find predictive values of NT-proBNP in patients with 
renal failure requiring dialysis and undergoing OPCAB, as this 
patient population was excluded from our study. In addition, 
it needs to be determined whether NT-proBNP combined with 
clinical scoring systems could better predict early outcomes 
after cardiac surgery in patients with GFR ≥ 90 ml/min/1.73 m2.
    In conclusion, preoperative NT-proBNP levels may be a 
potential predictive marker for early postoperative compli-
cations in patients who may require further hemodynamic 
optimization during the perioperative period, with eGFR under 
90 ml/min/1.73 m2 undergoing OPCAB. 
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